Clinical Trials Directory

Trials / Unknown

UnknownNCT04267575

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Jerome Canady, M.D. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated in high-temperature laboratory conditions. Plasma coagulators are currently used routinely as surgical tools with multiple applications that create temperatures between 37° C to 43°C and cause thermal injury. Earlier studies demonstrated the non-aggressive nature of cold plasma. As evidence accumulates, it is becoming clear that low-temperature cold plasma has an increasing role in biomedical applications.

Conditions

Interventions

TypeNameDescription
DEVICECanady Helios Cold Plasma ScalpelDevice used to distribute cold plasma energy at the resected tumor margins.

Timeline

Start date
2019-07-30
Primary completion
2021-04-14
Completion
2023-04-14
First posted
2020-02-13
Last updated
2021-08-09
Results posted
2021-08-09

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04267575. Inclusion in this directory is not an endorsement.